In the clinical specimens study, researchers found that RRM2B significantly related to better overall survival in stage IV CRC patients (HR = 0.40, 95% CI 0.18–0.86, p = 0.016) of the training set [25]. The gene discussed is RRM2B; the disease is colorectal carcinoma.